We previously reported that OT-101, a TGFB2-targeting S-ODN, exhibited promising single-agent clinical activity in adult patients with recurrent or refractory glioblastoma and anaplastic astrocytoma when administered intratumorally via CED [37]. Here, TGFB2 is linked to glioblastoma.